Trial Profile
A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Sugemalimab (Primary)
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Sponsors CStone Pharmaceuticals
- 30 Jun 2022 Status changed from active, no longer recruiting to completed.
- 16 Feb 2022 Planned End Date changed from 1 Dec 2021 to 31 Mar 2022.
- 20 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.